Plasmapheresis and plasma exchanges;usefulness in covid-19 critically ill patients

Phase 2

Recruiting

• Conditions: Covid-19.; COVID-19 Disease; U07.1

• Registration Number: IRCT20150107020592N23
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 15 June 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

age of patients ranged between 8 to 16 years2.COVID-19 POSITIVE3. interleukin above 6 4.Patients hospitalized in the intensive care unit5.Increased respiration rate (be30 beats / min), difficulty breathing, cyanosis of the lips6.Oxygen saturation percentage =93%
.COVID-19 positive
interleukin above 6
Patients hospitalized in the intensive care unit
Increased respiration rate (be30 beats / min), difficulty breathing, cyanosis of the lips
Oxygen saturation percentage =93%,PaO2 / FiO2 =300 mmHg
Patients with covid-19 disease receiving antiretroviral therapy such as Favipiravir ,remdesivir, and kaletra have experienced an increase in interleukin and a cytokine storm during treatment.

Exclusion Criteria

Patients treated with other interleukin-lowering methods, such as Actemra

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Oxygen percentage. Timepoint: One day before the procedure and one day and four days and seven days after the procedure. Method of measurement: Pulse Oximeter device.;Interleukin 6 level. Timepoint: Before the procedure and one day and six days and seven days after the three-phase plasmapheresis. Method of measurement: Lab kit.